Cancer chemopreventive activity of resveratrol

Drugs under Experimental and Clinical Research

Volumn 25, Issue 2-3, 1999, Pages 65-77

  Jang, M ^a   Pezzuto, J M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMUTAGENIC AGENT; ANTIOXIDANT; ARACHIDIC ACID; CYCLOOXYGENASE 2; DRUG METABOLIZING ENZYME; ENZYME INHIBITOR; GLUTATHIONE; HYDROGEN PEROXIDE; MYELOPEROXIDASE; NITRIC OXIDE SYNTHASE; PEROXIDASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN SYNTHASE; PROTEIN C FOS; RESVERATROL; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; CANCER PREVENTION; CARCINOGENESIS; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; LEUKEMIA CELL; MOUSE; NONHUMAN; ONCOGENE C FOS; OXIDATIVE STRESS; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTICARCINOGENIC AGENTS; BENZIDINES; BLOTTING, WESTERN; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MUTAGENICITY TESTS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PEROXIDASES; PHENYLBUTAZONE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SALMONELLA TYPHIMURIUM; STILBENES;

EID: 0032994292     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (93)

1. Nonomura, S., Kanagawa, H., Makimoto, A. Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-jo-kon (Polygonum cuspidatum Sieb, et Zucc.). Yakugaku Zasshi, 83, 988, 1963.
2. Langcake, P., Pryce, R.J. The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol. Plant Pathol., 9, 77, 1976.
3. Langcake P., Pryce R.J. The production of resveratrol and the viniferins by grapevines in response to ultraviolet irradiation. Phytochemistry 16, 1193, 1977.
4. Langcake P. Disease resistance of Vitis spp. and the production of the stress metabolites resveratrol, γ-viniferin, α-viniterin and pterostilbene. Physiol. Plant Pathol., 18, 213, 1981.
5. Hillis W.E., Hart, J.H., Yazaki, Y. Polyphenols of Eucalyptus sideroxylon wood. Phytochemistry, 13, 1591, 1974.
6. Hathway, D.W., Seakins, J.W.T. Hydroxystilbenes of Eucalyptus wandoo. Biochem. J., 72, 369, 1959.
7. Rolfs C.H., Kindl, H. Stilbene synthase and chalcone synthase. Two different constitutive enzymes in cultured cells of Picea excelsa. Plant Physiol., 75, 489, 1984.
8. Ingham J.L. 3,5,4′-Trihydroxystilbene as a phytoalexin from groundnuts (Arachis hypogaea). Phytochemistry, 15, 1791, 1976.
9. Schoeppner A., Kindl H. Purification and properties of a stilbene synthase from induced cell suspension cultures of peanut. J. Biol. Chem., 259, 6806, 1984.
10. Anjaneyulu A.S.R., Reddy A.V.R., Reddy D.S.K., Ward R.S., Adhikesavalu D., Cameron T.S. Pacharin: a new dibenzo(2,3-6,7)oxepin derivative from Bauhinia racemosa lamk. Tetrahedron, 40, 4245, 1984.
11. Hanawa F., Tahara S., Mizutani, J. Antifungal stress compounds from Veratrum grandiflorurn leaves treated with cupric chloride. Phytochemistry, 31, 3005, 1992.
12. Kumar R.J., Jyostna D., Krupadanam G.L., Srimannarayana, G. Phenanthrene and stilbenes from Pterolobium hexapetallum. Phytochemistry, 27, 3625, 1988.
13. Arora M.K., Strange R.N. Phytoalexin accumulation in groundnuts in response to wounding. Plant Sci., 7B, 157, 1991.
14. Arichi H., Kimura Y., Okuda H., Baba K., Kozawa M., Arichi S. Effects of stilbene components of the roots of Polygonum cuspidatum SIEB. et ZUGG. on lipid metabolism. Chem. Pharm. Bull., 30, 1766, 1982.
15. Kimura Y., Lkuda H., Arichi, S. Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim. Biophys. Acta, 834, 275, 1985.
16. Frankel E.N., Waterhouse A.L., Kinsella, J.E. Inhibition of human LDL oxidation by resveratrol. Lancet, 341, 1103, 1993.
17. Pace-Asciak C.R., Hahn S., Diamandis E.P., Soleas G., Goldberg D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: Implications for protection against coronary heart disease. Clin. Chim. Acta, 235, 207, 1995.
18. Bertelli A.A.E., Giovannini L., Giannessi D., et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int. J. Tissue React., 17, 1, 1995.
19. Goldberg D.M., Ng E., Karumanchiri A., Yan J., Diamandis E.P., Soleas G.J. Assay of resveratrol glycosides and isomers in wine by direct-injection high-performance liquid chromatography. J. Chromatogr., 708, 89, 1995.
20. Goldberg D.M., Yan J., Ng E., et al. A global survey of transresveratrol concentrations in commercial wines. Am. J. Eno. Vitic., 46, 159, 1995.
21. Goldberg D.M., Hahn S.E., Parkes J.G. Beyond alcohol: Beverage consumption and cardiovascular mortality. Clin. Chim. Acta, 237, 155, 1995.
22. Ragazzi E., Froldi G., Fassina G. Resveratrol activity on guinea pig isolated trachea from normal and albumin-sensitized animals. Pharmacol. Res. Commun., 20, 79, 1988.
23. Man Y.N., Ryn S.Y., Han B.H. Antioxidant activity of resveratrol closely correlates with its monoamine oxidase-A inhibitory activity. Arch. Pharmacol. Res., 13, 132, 1990.
24. Murakami S., Arai I., Muramatsu M., et al. Effect of stilbene derivatives on gastric H',K'-ATPase. Biochem. Pharmacol., 44, 1947, 1992.
25. Jayatrake G.S., Jayasuriya J., Lee E.S., et al. Kinase inhibitors from Polygonum cuspidatum. J. Nat. Prod., 56, 1805, 1993.
26. Jang M., Cai L., Udeani G.O., et al. Cancer chemopreventive activity of resveratrol, a natural product derived front grapes. Science, 275, 218, 1997.
27. Giardiello F.M., Offerhaus G.J.A., DuBois. R.N. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur. J. Cancer, 31, 1071, 1995.
28. Jang M., Pezzuto J. M. Resveratrol blocks eicosanoid production and chemical-induced transformation: Implications for cancer chemoprevention. Pharm. Biol., 36 (Suppl.), 28, 1998.
29. Nigam S., Zakrzewicz A. Tumour cell proliferation by thromboxane A : Receptor-mediated event. In: Samuelson B., (Ed.). "Advances in Prostaglandin. Thromboxane and Leukotriene Research." Vol. 21, Raven Press, New York 1990. pp. 925-928.
30. Goodwin J.S., Ceuppens J.L. Prostaglandins, cellular immunity and cancer. In: Goodwin J.S. (Ed.). "Prostaglandins and Immunity." Martinus Nijhoff Publishing, Boston, 1985, pp. 1-34.
31. Smith B.J., Curtis J.F., Eling, T.E. Bioactivation of xenobiotics by prostaglandin H synthase. Chem.-Biol. Interact., 79, 245, 1991.
32. Blumberg P.M. In vitro studies on the mode of action of the phorbol esters, potent tumor promoters. Part 1. CRC Crit. Res. Toxicol., 8, 153, 1980.
33. Blumberg P.M. In vitro studies on the mode of action of the phorbol esters, potent tumor promoters. Part 2. CRC Crit. Rev. Toxicol., 8, 199, 1981.
34. Boutwell R.K. The function and mechanism of promoters of carcinogenesis. CRC Crit. Rev. Toxicol., 2, 419, 1974.
35. Diamond L., O'Brien T.G., Baird W.M. Tumor promoters and the mechanism of tumor promotion. Adv. Cancer Res., 32, 1, 1980.
36. Raick, A.N. Ultrastructural, histological, and biochemical alterations produced by 12-O-tetradecanoyl-phorbol-13-acetate on mouse epidermis and their relevance to skin tumor promotion. Cancer Res., 33, 269, 1973.
37. Frenkel K., Chrzan K. Hydrogen peroxide formation and DNA modification by tumor promoter-activated polymorphonuclear leukocytes Carcinogenesis, 8, 455, 1987.
38. Wei H., Frenkel K. In vivo formation of oxidized DNA bases in tumor promoter-treated mouse skin. Cancer Res., 51, 4443, 1991.
39. Solanki V., Rana R.S., Slaga, T. J. Diminution of mouse epidermal superoxide dismutase and catalase activities by tumor promoters. Carcinogenesis. 2, 1141, 1981.
40. Kinsella A.R., Gainer H.S.S., Butler, J. Investigation of a possible role for superoxide anion production in tumor promotion. Carcinogenesis, 4, 717, 1983.
41. Perchellet J.P., Perchellet E.M., Orten D.K., Schneider B.A. Inhibition of the effects of 12-O-tetradecanoylphorbol-13-acetate on mouse epidermal glutathione peroxidase and ornithine decarboxylase activities by gtutathrone level-raising agents and selenium-containing compounds. Cancer Lett., 26, 283, 1985.
42. Perchellet J.P., Owen M.D., Posey T.D., Orten D.K., Schneider B.A. Inhibitory eftects of glutathione level-raising agents and p-α-tocopherol on ornithine decarboxylase induction and mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Carcinogenesis 6, 567, 1985.
43. Jang M., Pezzuto, J.M. Effects of resveratrol on 12-O-tetradocanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin. Cancer Lett. 134, 81, 1998.
44. Bredt D.S., Snyder S.H. Nitric oxide, a physiologic messenger molecule. Annu. Rev. Biochem., 63, 175, 1994.
45. Knowles R.G., Moncada, S. Nitric oxide syntnases in mammals. Biochem. J., 298, 249, 1994.
46. Leibovich S.J., Polverini P.J., Fong T.W., Harlow L.A., Koch A.E. Production of angiogenic activity by human monocytes requires an i-arginine/nitric oxide-synthase-dependent effector mechanism. Proc. Natl. Acad. Sci. USA, 91, 4190, 1994.
47. Thomsen L.L., Lawton F.G., Knowles R.G., Beesley J.E., Riveros-Moreno V., Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res., 54, 1352, 1994.
48. Maron D.M., Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res., 113, 173, 1983.
49. Hughes M.F., Mason R.P., Eling T.E. Prostaglandin hydroperoxidase-dependent oxidation of phenylbutazone: Relationship to inhibition of prostaglandin cyclooxygenase. Mol. Pharmacol., 34, 186, 1988.
50. Eling T.E., Thompson D.C. Foureman G.L., Curtis J.F., Hughes M.F. Prostaglandin H synthase and xenobiotic oxidation. Ann. Rev. Pharmacol. Toxicol., 30, 1, 1990.
51. Ito N., Imaida, K. Strategy of research for cancer chemoprevention. Terat. Carcinogen Mutag., 12, 79, 1992.
52. Huang M.T., Ferraro T., Ho C.T. Cancer chemoprevention by phytochemicals in fruits and vegetables. In: Huang M.T., Ho C.T. (Eds.). "Food Phytochemicals for Cancer Chemoprevention I" ACS Symposium Series No. 546. American Chemical Society Books, Washington DC, 1992, pp. 1-16
53. Wattenberg, L.W. Chemoprevention of cancer. Cancer Res., 45, 1, 1985.
54. Reed G.A., Ryan M.J. Peroxyl radical-dependent activation of 2-aminofluorene derivatives. Proc. Am. Assoc. Cancer Res., 29, 498, 1988.
55. Flammang T.J., Yamazoe Y., Benson R.W., Roberts D.W., Potter D.W. Arachidonic acid-dependent peroxidative activation of carcinogenic arylamines by extrahepatic human tissue microsomes. Cancer Res., 49, 1977, 1989.
56. Yamazoe Y., Zenser T.V., Miller D.W., Kadlubar F.F. Mechanism of formation and structural characterization of DNA adducts derived from peroxidative activation of benzidine. Carcinogenesis, 9, 1635, 1988.
57. Krauss R.S., Eling T.E. Formation of unique arylamine: DNA adducts from 2-aminofluorene activated by prostaglandin H synthase. Cancer Res., 45, 1680, 1985.
58. Demopoulos H.B., Pietronigro D.D., Seligmann M.L. The development of secondary pathology with free radical reactions as a threshold mechanism. J. Amer. Coll. Toxicol., 2, 173, 1983.
59. Roman-Franco, A.A. Non-enzymatic extramicrosomal bioactivation of chemical carcinogens by phagocytes: A proposed new pathway. J. Theor. Biol. 97, 543, 1982.
60. Jones P.A., Benedict W.F., Baker M.S., Mondal S., Rapp U., Heidelberger C. Oncogenic transformation of C3H/10T1/2 clone 8 mouse embryo cells by halogenated pyrimidine nucleosides. Cancer Res., 36, 101, 1976.
61. Terzaghi M., Little J.B. X-irradiation-induced transformation in a C3H mouse embryo-derived cell line. Cancer Res. 36, 1367, 1976.
62. Kolman A., Harms-Ringdahl, M. Radiation-induced neoplastic transformation of stationary phase C3H/10T1/2 cells in response to different dose rate and to post-irradiation treatment with tumor promoter. Chem.-Biol.Interact., 101, 59, 1996.
63. Ji C., Marnett, L.J. Oxygen radical-dependentepoxidation of (7S,8S)-dihydroxy-7,8-dihydrobenzol[a]pyrene in mouse skin in vivo. J. Biol. Chem., 267, 17842, 1992.
64. Kumar S., Antony M., Mehrotra N.K. Oxidized glutathione reductase activity in mouse epidermis: TPA induced change and its modulation by vitamin A. Biochem. Biophys. Res. Commun., 125, 967, 1984.
65. Fischer S.M., Baldwin J.K., Jasheway D.W., Patrick K.E., Cameron G.S. Phorbol ester induction of 8-lipoxygenase in inbred SENCAR (SSIN) but not C57BL/6J mice correlated with hyperplasia, edema, and oxidant generation but not ornithine decarboxylase induction. Cancer Res., 48, 658, 1988.
66. Subbaramaiah K., Chung W. J., Michaluart P., et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem., 273, 21875, 1998.
67. Kennard M.D., Kang D-C., Montgomery R.L., Butler, A.P. Expression of epidermal ornithine decarboxylase and nuclear protooncogenes in phorbol ester tumor promotion-sensitive and -resistant mice. Mol. Carcinogen. 12, 14, 1995.
68. Schuermann M., Neuberg M., Hunter J.B., et al. The leucine repeat motif in fos protein mediates complex formation with Jun/AP-1 and is required lor transformation. Cell, 56, 507, 1989.
69. Roy S., Chapin R.B., Cain K.J., Charboneau R.G., Ramakrishnan S., Barke R.A. Morphine inhibits transcriptional activation oi IL-2 in mouse thymocytes. Cell. Immunol., 179, 1, 1997.
70. Sporn M.B., Roberts A.B. Transforming growth factor β: recent progress and new challenges. J. Cell. Biol., 119, 1017, 1992.
71. Balkwill F.R., Burke, F. The cytokine network, Immunol. Today, 10, 299, 1989.
72. Akhurst R.J., Fee F., Balmain A. Localized production of TGF beta mRNA in tumour promoter-stimulated mouse epidermis. Nature, 331, 363, 1988.
73. Urban J.L., Shepard H.M., Rothstein J.L., Sugarman B.J., Shreiber H. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc. Natl. Acad. Sci. USA, 83, 5233, 1986.
74. Beissert S., Bergholz M., Waase I., et al. Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: In vivo analysis by in situ hybridization. Proc. Natl. Acad. Sci. USA, 86, 5064, 1989.
75. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterolgy, 107, 1183, 1994.
76. Prescott S.M., White R.L. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell, 87, 783, 1996.
77. A71G knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803, 1996.
78. Cobbs C.S., Brenman J.E., Aldape K.D., Bredt D.S., Israel M.A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res., 55, 727, 1995.
79. Takahashi M., Fukuda K., Ohata R., Sugimura T., Wakabayashi K. Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res., 57, 1233, 1997.
80. Misko T.P., Trotter J.L., Cross A.H. Mediation of inflammation by encephalitogenic cells: Interferon γ induction of nitric oxide synthase and cyclooxygenase 2. J. Neuroimmunol., 61, 195, 1995.
81. Hooper D.G., Bagasra O., Marin J.C., et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: Implication for the treatment of multiple sclerosis. Proc. Natl. Acad. Sci. USA, 94, 2528, 1997.
82. Goodwin J.L., Uemura R., Cunnick, J.E. Microglial release of nitric oxide by the synergistic action of β-amyloid and IFN-γ. Brain Res. ,692, 207, 1995.
83. Good P.F., Werner P., Hsu A., Olanow C.W., Perl D.P. Evidence for neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol., 149, 21, 1996.
84. Simonian N.A., Coyle J.T. Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol., 36, 83, 1996.
85. Hantraye P., Brouillet E., Ferrante R., et al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced Parkinsonism in baboons. Nature Med., 2, 1017, 1996.
86. Tamir S., Tannenbaum S.R. The role of nitric oxide (NO) in the carcinogenic process. Biochim. Biophys. Acta, 1288, 31, 1996.
87. Ohshima H., Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: Possible role of nitric oxide in carcinogenesis. Mutat. Res., 305, 253, 1994.
88. Bastian N.R., Yim C.Y., Hibbs J.B. Jr., Samlowski W.E. Induction of iron-derived EPR signals in marine cancers by nitric oxide. Evidence for multiple intracellular targets. J. Biol. Chem., 269, 5127, 1994
89. Rosbe K.W., Prazma J., Petrusz P., Mims W., Ball S.S., Weissler M.C. Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck. Otolaryngol. Head Neck Surg. 113, 541, 1995.
90. Thomsen L.L., Miles D.W., Happerfield L., Bobrow L.G., Knowless R.G., Moncada S. Nitric oxide synthase in human breast cancer. Br. J. Cancer 72, 41, 1995.
91. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329, 2002, 1993.
92. Maeda H., Akaike T., Yoshida M., Suga M. Multiple functions of nitric oxide in pathophysiology and microbiology: Analysis by a new nitric oxide scavenger J. Leukoc. Biol., 56, 588, 1994.
93. Maeda H., Akaike T., Yoshida M., Sato K., Noguchi Y. A new nitric oxide scavenger, imidazolineoxyl N-oxide derivative, and its effect in pathophysiology and microbiology. In: Koprowski, H., Maeda, H. (Eds.). "The Role of Nitric Oxide in Physiology and Pathophysiology." Springer-Verlag, Berlin. 1995, pp. 37-55.